Moderna shares rise 5.82% intraday after exceeding 2025 revenue forecast and cutting operating expenses.

Moderna Inc. surged 5.82% intraday after reporting preliminary 2025 revenues of $1.9 billion, exceeding the midpoint of its prior guidance, alongside a $200 million reduction in operating expenses and a projected $8.1 billion cash balance. The update highlighted disciplined cost control, robust cash reserves, and 2026 guidance targeting up to 10% revenue growth, bolstering investor confidence. Key milestones, including regulatory filings for its influenza vaccine and progress in oncology trials, further reinforced the company’s pipeline potential. The intraday rally aligned with these positive financial and operational developments, which addressed post-pandemic challenges and signaled stabilization in its business trajectory.